Lisa Demeter
Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
HIV-1 | 65 | 1995 | 93 |
Why?
| Anti-HIV Agents | 35 | 1996 | 44 |
Why?
| HIV Infections | 45 | 1995 | 136 |
Why?
| Reverse Transcriptase Inhibitors | 25 | 1995 | 19 |
Why?
| HIV Reverse Transcriptase | 23 | 1995 | 16 |
Why?
| Virus Replication | 21 | 1992 | 90 |
Why?
| Drug Resistance, Viral | 21 | 2003 | 17 |
Why?
| Mutation | 21 | 1995 | 340 |
Why?
| HIV Protease Inhibitors | 10 | 1997 | 25 |
Why?
| RNA, Viral | 26 | 1990 | 91 |
Why?
| Acquired Immunodeficiency Syndrome | 10 | 1995 | 85 |
Why?
| Zidovudine | 14 | 1995 | 23 |
Why?
| Indinavir | 8 | 1997 | 6 |
Why?
| Drug Monitoring | 5 | 2003 | 33 |
Why?
| Drug Resistance, Microbial | 14 | 1997 | 53 |
Why?
| Ribonuclease H | 5 | 1999 | 15 |
Why?
| Delavirdine | 6 | 1997 | 7 |
Why?
| HIV | 6 | 2001 | 32 |
Why?
| Benzoxazines | 7 | 2003 | 14 |
Why?
| Lamivudine | 5 | 1997 | 18 |
Why?
| DNA, Viral | 12 | 1990 | 98 |
Why?
| Microbial Sensitivity Tests | 8 | 1995 | 71 |
Why?
| Viral Load | 14 | 1997 | 53 |
Why?
| CD4 Lymphocyte Count | 18 | 1995 | 50 |
Why?
| Recombination, Genetic | 2 | 2004 | 78 |
Why?
| Antiretroviral Therapy, Highly Active | 7 | 2003 | 27 |
Why?
| Humans | 75 | 1990 | 1856 |
Why?
| HIV Protease | 3 | 2004 | 7 |
Why?
| Papillomaviridae | 7 | 1990 | 37 |
Why?
| Dideoxynucleosides | 3 | 2003 | 8 |
Why?
| Drug Therapy, Combination | 16 | 1995 | 189 |
Why?
| RNA-Directed DNA Polymerase | 2 | 1995 | 28 |
Why?
| Tumor Virus Infections | 4 | 1992 | 31 |
Why?
| Piperazines | 4 | 1995 | 57 |
Why?
| Oxazines | 3 | 2003 | 16 |
Why?
| Cell Line | 11 | 1999 | 375 |
Why?
| Genes, Viral | 4 | 1998 | 37 |
Why?
| Didanosine | 3 | 1995 | 8 |
Why?
| Adult | 35 | 1990 | 1317 |
Why?
| Mutagenesis, Site-Directed | 5 | 2000 | 126 |
Why?
| Flow Cytometry | 2 | 2006 | 216 |
Why?
| Female | 38 | 1990 | 1643 |
Why?
| DNA Replication | 1 | 2006 | 75 |
Why?
| Models, Biological | 3 | 2006 | 410 |
Why?
| Gene Products, gag | 1 | 2004 | 14 |
Why?
| Genome, Viral | 1 | 2004 | 21 |
Why?
| Male | 32 | 1990 | 1553 |
Why?
| Leukocytes, Mononuclear | 2 | 1998 | 67 |
Why?
| Genotype | 10 | 1998 | 175 |
Why?
| Antiviral Agents | 4 | 1995 | 91 |
Why?
| Sequence Analysis, DNA | 3 | 1998 | 110 |
Why?
| Treatment Outcome | 10 | 1996 | 661 |
Why?
| AIDS-Related Opportunistic Infections | 1 | 2002 | 41 |
Why?
| Base Sequence | 7 | 1995 | 371 |
Why?
| Mutation, Missense | 3 | 2010 | 59 |
Why?
| Pneumonia, Pneumocystis | 1 | 2002 | 28 |
Why?
| Laboratories | 2 | 1998 | 21 |
Why?
| Phenotype | 7 | 1997 | 303 |
Why?
| HIV Envelope Protein gp120 | 1 | 2000 | 15 |
Why?
| Cysteine | 1 | 2001 | 52 |
Why?
| Tyrosine | 1 | 2001 | 71 |
Why?
| Defective Viruses | 1 | 1999 | 13 |
Why?
| Middle Aged | 15 | 1993 | 1161 |
Why?
| Cells, Cultured | 8 | 1992 | 447 |
Why?
| Interferon-gamma | 4 | 2000 | 133 |
Why?
| Uterine Cervical Neoplasms | 2 | 1992 | 55 |
Why?
| Kinetics | 4 | 1999 | 349 |
Why?
| Papillomavirus Infections | 2 | 1994 | 39 |
Why?
| Carcinoma in Situ | 2 | 1992 | 26 |
Why?
| Anti-Retroviral Agents | 3 | 2003 | 13 |
Why?
| Condylomata Acuminata | 5 | 1990 | 16 |
Why?
| Indoles | 1 | 1997 | 69 |
Why?
| Nelfinavir | 3 | 2003 | 3 |
Why?
| Reagent Kits, Diagnostic | 2 | 2004 | 16 |
Why?
| HIV Core Protein p24 | 3 | 1998 | 17 |
Why?
| Carcinoma, Squamous Cell | 2 | 1992 | 111 |
Why?
| Papilloma | 1 | 1994 | 7 |
Why?
| Drug Administration Schedule | 3 | 2009 | 191 |
Why?
| Prevalence | 3 | 1993 | 281 |
Why?
| Double-Blind Method | 6 | 1990 | 274 |
Why?
| Penile Neoplasms | 1 | 1993 | 12 |
Why?
| Clinical Trials as Topic | 3 | 2000 | 251 |
Why?
| Keratinocytes | 1 | 1994 | 36 |
Why?
| Codon | 3 | 1998 | 41 |
Why?
| Antigens, Neoplasm | 1 | 1994 | 56 |
Why?
| Treatment Failure | 4 | 2000 | 88 |
Why?
| Receptors, Immunologic | 1 | 1992 | 36 |
Why?
| Point Mutation | 2 | 1999 | 122 |
Why?
| Molecular Sequence Data | 4 | 1995 | 404 |
Why?
| Virus Cultivation | 2 | 1992 | 24 |
Why?
| HeLa Cells | 2 | 1999 | 107 |
Why?
| Computer Simulation | 2 | 2008 | 134 |
Why?
| Virology | 1 | 2010 | 13 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 1997 | 91 |
Why?
| 5' Untranslated Regions | 2 | 1999 | 19 |
Why?
| HIV Envelope Protein gp41 | 1 | 2010 | 4 |
Why?
| Virus Latency | 1 | 2010 | 11 |
Why?
| Sensitivity and Specificity | 4 | 2003 | 427 |
Why?
| Virulence | 1 | 2010 | 48 |
Why?
| Virion | 1 | 2010 | 24 |
Why?
| Nuclear Proteins | 1 | 1994 | 139 |
Why?
| Pregnancy Complications, Infectious | 3 | 1995 | 35 |
Why?
| Linear Models | 2 | 2006 | 151 |
Why?
| Software | 1 | 2010 | 92 |
Why?
| Internet | 1 | 2010 | 64 |
Why?
| Virus Physiological Phenomena | 1 | 2008 | 5 |
Why?
| Polymerase Chain Reaction | 5 | 1997 | 279 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 1997 | 113 |
Why?
| T-Lymphocytes | 3 | 2001 | 182 |
Why?
| Biometry | 1 | 2008 | 32 |
Why?
| Reproducibility of Results | 3 | 1998 | 391 |
Why?
| Lymphocyte Count | 2 | 1997 | 38 |
Why?
| Antigens, Fungal | 2 | 2002 | 11 |
Why?
| Peptide Fragments | 1 | 2010 | 144 |
Why?
| RNA, Transfer, Amino Acyl | 2 | 2001 | 10 |
Why?
| Mice, SCID | 1 | 2007 | 61 |
Why?
| Stavudine | 2 | 1997 | 3 |
Why?
| Developing Countries | 1 | 2006 | 28 |
Why?
| Cervical Intraepithelial Neoplasia | 1 | 2006 | 16 |
Why?
| RNA, Transfer, Lys | 1 | 2006 | 6 |
Why?
| Antigens, Thy-1 | 1 | 2006 | 22 |
Why?
| Mathematics | 1 | 2006 | 75 |
Why?
| Pregnancy | 5 | 1995 | 455 |
Why?
| Mice | 3 | 1992 | 623 |
Why?
| Interferons | 2 | 1996 | 39 |
Why?
| Research Design | 1 | 2008 | 169 |
Why?
| Genes, Reporter | 1 | 2006 | 111 |
Why?
| Amino Acid Substitution | 1 | 2006 | 68 |
Why?
| Animals | 4 | 1992 | 1031 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2006 | 52 |
Why?
| Nucleosides | 1 | 2004 | 10 |
Why?
| DNA Primers | 1 | 2006 | 208 |
Why?
| Disease Progression | 3 | 1997 | 244 |
Why?
| Templates, Genetic | 1 | 2004 | 22 |
Why?
| RNA, Messenger | 1 | 1992 | 394 |
Why?
| Phosphonic Acids | 1 | 2003 | 9 |
Why?
| Cercopithecus aethiops | 1 | 2004 | 67 |
Why?
| COS Cells | 1 | 2004 | 73 |
Why?
| Sequence Alignment | 1 | 2004 | 114 |
Why?
| Adenine | 1 | 2003 | 26 |
Why?
| Retrospective Studies | 4 | 1995 | 653 |
Why?
| Cloning, Molecular | 1 | 2004 | 183 |
Why?
| Mutagenesis | 2 | 1999 | 74 |
Why?
| Oncogene Proteins, Viral | 2 | 1992 | 29 |
Why?
| Aged | 4 | 1999 | 988 |
Why?
| DNA, Fungal | 1 | 2002 | 27 |
Why?
| Proviruses | 2 | 1997 | 8 |
Why?
| Pneumocystis | 1 | 2002 | 13 |
Why?
| Clinical Protocols | 1 | 2001 | 93 |
Why?
| Vaccines, DNA | 1 | 2001 | 16 |
Why?
| Adenosine | 1 | 2001 | 57 |
Why?
| 3' Untranslated Regions | 1 | 2001 | 21 |
Why?
| Hydrolysis | 1 | 2001 | 57 |
Why?
| Papillomavirus Vaccines | 1 | 2001 | 19 |
Why?
| Heteroduplex Analysis | 1 | 2000 | 4 |
Why?
| Dehydroepiandrosterone Sulfate | 1 | 2000 | 8 |
Why?
| Sequence Analysis | 1 | 2000 | 23 |
Why?
| Guidelines as Topic | 1 | 2001 | 77 |
Why?
| Viral Vaccines | 1 | 2001 | 35 |
Why?
| Practice Guidelines as Topic | 1 | 2003 | 174 |
Why?
| Autonomic Nervous System | 1 | 2000 | 41 |
Why?
| Evolution, Molecular | 1 | 2000 | 45 |
Why?
| Predictive Value of Tests | 1 | 2002 | 321 |
Why?
| Logistic Models | 1 | 2001 | 251 |
Why?
| Gene Amplification | 1 | 1998 | 22 |
Why?
| Drug Eruptions | 1 | 1998 | 26 |
Why?
| Drug Resistance | 2 | 1995 | 83 |
Why?
| Specimen Handling | 2 | 2006 | 52 |
Why?
| Interferon-alpha | 2 | 1990 | 43 |
Why?
| Immunotherapy | 1 | 1997 | 48 |
Why?
| Cell Proliferation | 2 | 2008 | 227 |
Why?
| Biopsy | 1 | 1996 | 207 |
Why?
| Cohort Studies | 1 | 1998 | 332 |
Why?
| Infectious Disease Transmission, Vertical | 1 | 1995 | 27 |
Why?
| Genital Neoplasms, Female | 1 | 1994 | 27 |
Why?
| Genital Neoplasms, Male | 1 | 1994 | 16 |
Why?
| Laryngeal Neoplasms | 1 | 1994 | 9 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 1994 | 26 |
Why?
| Immunoenzyme Techniques | 1 | 1994 | 125 |
Why?
| Blotting, Southern | 1 | 1993 | 69 |
Why?
| Regression Analysis | 3 | 1990 | 256 |
Why?
| Virus Integration | 1 | 1993 | 17 |
Why?
| Area Under Curve | 2 | 2000 | 47 |
Why?
| In Situ Hybridization | 1 | 1994 | 135 |
Why?
| Vaginal Smears | 2 | 1999 | 31 |
Why?
| Receptors, Laminin | 1 | 1992 | 7 |
Why?
| Follow-Up Studies | 3 | 1990 | 553 |
Why?
| Warts | 1 | 1992 | 13 |
Why?
| Nucleic Acid Hybridization | 1 | 1992 | 94 |
Why?
| Pyridazines | 1 | 2011 | 8 |
Why?
| Nevirapine | 1 | 2011 | 9 |
Why?
| Patient Selection | 2 | 2003 | 155 |
Why?
| Blotting, Northern | 1 | 1992 | 151 |
Why?
| Neoplasm Invasiveness | 1 | 1992 | 105 |
Why?
| RNA, Complementary | 1 | 2010 | 12 |
Why?
| Antigens, Bacterial | 1 | 2011 | 44 |
Why?
| Interferon Type I | 1 | 1990 | 22 |
Why?
| Antigens, Viral | 1 | 2011 | 53 |
Why?
| Calibration | 1 | 2010 | 37 |
Why?
| Ribonuclease H, Human Immunodeficiency Virus | 1 | 2010 | 3 |
Why?
| Drug Resistance, Multiple, Viral | 1 | 2010 | 2 |
Why?
| Quality Control | 1 | 2010 | 54 |
Why?
| Selection, Genetic | 1 | 2010 | 10 |
Why?
| Placebos | 1 | 2010 | 110 |
Why?
| Viremia | 1 | 2009 | 18 |
Why?
| Statistics, Nonparametric | 1 | 2010 | 141 |
Why?
| Cell Division | 1 | 1992 | 273 |
Why?
| Least-Squares Analysis | 1 | 2008 | 21 |
Why?
| Adolescent | 2 | 1993 | 891 |
Why?
| New York | 2 | 1999 | 422 |
Why?
| Nonlinear Dynamics | 1 | 2008 | 18 |
Why?
| Monte Carlo Method | 1 | 2008 | 40 |
Why?
| Acute Disease | 1 | 2009 | 271 |
Why?
| Lopinavir | 1 | 2007 | 11 |
Why?
| Ritonavir | 1 | 2007 | 10 |
Why?
| Safety | 2 | 1995 | 80 |
Why?
| Developed Countries | 1 | 2006 | 9 |
Why?
| Pyrimidinones | 1 | 2007 | 14 |
Why?
| Infant, Newborn | 2 | 1995 | 389 |
Why?
| Young Adult | 1 | 2010 | 380 |
Why?
| Herpesvirus 4, Human | 1 | 2006 | 34 |
Why?
| Maternal-Fetal Exchange | 1 | 2006 | 49 |
Why?
| Cytomegalovirus | 1 | 2006 | 42 |
Why?
| Fibroblasts | 2 | 1992 | 179 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 224 |
Why?
| Prospective Studies | 1 | 2009 | 545 |
Why?
| Algorithms | 1 | 2008 | 226 |
Why?
| Pharmacogenetics | 1 | 2003 | 9 |
Why?
| Vesicular stomatitis Indiana virus | 1 | 2003 | 13 |
Why?
| Peptides | 1 | 2006 | 154 |
Why?
| HIV Seropositivity | 1 | 2003 | 24 |
Why?
| Protease Inhibitors | 1 | 2003 | 39 |
Why?
| Chronic Disease | 1 | 2006 | 267 |
Why?
| Health Planning Guidelines | 1 | 2003 | 19 |
Why?
| Transcription, Genetic | 2 | 1992 | 253 |
Why?
| HLA Antigens | 1 | 2003 | 38 |
Why?
| Patient Compliance | 1 | 2003 | 113 |
Why?
| Methylation | 1 | 2001 | 36 |
Why?
| Recurrence | 2 | 1990 | 261 |
Why?
| Interleukin-5 | 1 | 2001 | 20 |
Why?
| Capsid Proteins | 1 | 2001 | 19 |
Why?
| beta 2-Microglobulin | 1 | 2000 | 17 |
Why?
| Species Specificity | 1 | 2001 | 186 |
Why?
| Th1 Cells | 1 | 2000 | 33 |
Why?
| Polyneuropathies | 1 | 2000 | 14 |
Why?
| Respiration | 1 | 2000 | 78 |
Why?
| Th2 Cells | 1 | 2000 | 36 |
Why?
| Outpatient Clinics, Hospital | 1 | 1999 | 37 |
Why?
| Europe | 1 | 1999 | 54 |
Why?
| Interleukin-4 | 1 | 2000 | 62 |
Why?
| Cervix Uteri | 1 | 1999 | 38 |
Why?
| Risk Assessment | 1 | 2003 | 324 |
Why?
| World Health | 1 | 1999 | 41 |
Why?
| Lymphocyte Activation | 1 | 2001 | 137 |
Why?
| Sex Characteristics | 1 | 2000 | 85 |
Why?
| Antibodies, Viral | 1 | 2001 | 104 |
Why?
| Heart Rate | 1 | 2000 | 138 |
Why?
| Transfection | 1 | 2001 | 237 |
Why?
| Cognition Disorders | 1 | 2000 | 107 |
Why?
| Cross-Sectional Studies | 1 | 1999 | 253 |
Why?
| Vaccines, Synthetic | 1 | 1997 | 30 |
Why?
| Cryosurgery | 1 | 1996 | 12 |
Why?
| Dose-Response Relationship, Drug | 1 | 1999 | 431 |
Why?
| Longitudinal Studies | 1 | 1997 | 195 |
Why?
| United States | 1 | 2003 | 604 |
Why?
| Combined Modality Therapy | 1 | 1996 | 219 |
Why?
| Prognosis | 1 | 1996 | 388 |
Why?
| 3T3 Cells | 1 | 1992 | 54 |
Why?
| Epithelium | 1 | 1992 | 101 |
Why?
| Bisexuality | 1 | 1990 | 9 |
Why?
| Homosexuality | 1 | 1990 | 17 |
Why?
| Injections, Subcutaneous | 1 | 1990 | 63 |
Why?
| Epithelial Cells | 1 | 1992 | 135 |
Why?
| Infant | 1 | 1995 | 464 |
Why?
| Risk Factors | 1 | 1996 | 555 |
Why?
| Sex Factors | 1 | 1990 | 284 |
Why?
| Recombinant Proteins | 1 | 1990 | 290 |
Why?
| Time Factors | 1 | 1995 | 896 |
Why?
| Cell Differentiation | 1 | 1992 | 262 |
Why?
|
|
Demeter's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
